A tumor necrosis factor related ligand

(19)

(11)

EP 1 591 530 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	22.04.2015 Bulletin 2015/17

(45)	Mention of the grant of the patent:
	25.02.2015 Bulletin 2015/09

(21)	Application number: 05011540.1

(22)	Date of filing: 07.08.1997

(51)

International Patent Classification (IPC):

C12N 15/28^(2006.01)
G01N 33/68^(2006.01)
C12N 15/11^(2006.01)
C12N 5/10^(2006.01)
A61K 38/19^(2006.01)
C12N 15/12^(2006.01)

C07K 14/525^(2006.01)
C07K 16/24^(2006.01)
A61K 48/00^(2006.01)
A61K 39/395^(2006.01)
C07K 14/705^(2006.01)

(54)	A tumor necrosis factor related ligand Tumornekrosefaktor-verwandter Ligand Ligand associé au facteur de nécrose tumorale

(84)	Designated Contracting States:
	AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	AL LT LV RO SI

(30)

Priority:

07.08.1996 US 23541 P
18.10.1996 US 28515 P
18.03.1997 US 40820 P

(43)	Date of publication of application:
	02.11.2005 Bulletin 2005/44

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	97935334.9 / 0956351

(73)	Proprietors:
	Biogen Idec MA Inc. Cambridge, Massachusetts 02142 (US) University of Geneva 1211 Genève 4 (CH)

(72)	Inventors:
	Chicheportiche, Yves 1208 Geneva (CH) Browning, Jeffrey L. Brookline, MA 02146 (US)

(74)	Representative: Adams, Harvey Vaughan John et al
	Mathys & Squire LLP The Shard 32 London Bridge Street London SE1 9SG The Shard 32 London Bridge Street London SE1 9SG (GB)

(56)

References cited: :

L. HILLIER ET AL: "The WashU-Merck EST project . yj77A08.r1 Homo sapiens cDNA clone 154742 5'" EMBL DATABASE ENTRY HS379117, ACCESSION NUMBER R55379, 28 May 1995 (1995-05-28), XP002049703
L. HILLIER ET AL: "The WashU-Merck EST project. yy19a08.s1 Homo sapiens cDNA clone 271670 3'" EMBL DATABASE ENTRY HS070272, ACCESSION NUMBER N35070, 19 January 1996 (1996-01-19), XP002049704
J,L. BROWNING ET AL: "Characterization of surface Lymphotoxin forms.Use of specific monoclonal antibodies and soluble receptors" JOURNAL OF IMMUNOLOGY., vol. 154, 1995, pages 33-46, XP002049706 BALTIMORE US
WILEY S R ET AL: "IDENTIFICATION AND CHARACTERIZATION OF A NEW MEMBER OF THE TNF FAMILY THAT INDUCES APOPTOSIS" IMMUNITY, vol. 3, no. 6, December 1995 (1995-12), pages 673-682, XP000672297
M. MARRA ET AL: "The WashU-HHMI Mouse EST project. my18d09.r1 Barstead mouse heart MPLRB3 Mus musculus cDNA clone 696209 5'" EMBL DATABASE ENTRY MMAA21610, ACCESSION NUMBER AA221610, 15 February 1997 (1997-02-15), XP002049707

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).